Table 1.
Categories of immune therapy
| Categories | Type | Substance (generic) | Target | TU types | |
|---|---|---|---|---|---|
| Passive | Targeted antibodies | Monoclonal antibodies | Bevacizumab, Cetuximab, Denosumab, Panitumumab, Rituximab, Trastuzumab … | CD20/33/52, VEGFA, EGFR, Her2, RANK | Leukemia, lymphoma, BRC, NSCLC, CRC, RCC, glioblastoma … |
| ADC | Ado-trastuzumab, brentuximab … |
HER2+ CD30 |
BRC, leukemia, lymphoma | ||
| Bispecific antibodies | Blinatumomab | Leukemia | |||
| Immunomodulators | Cytokines | Interferon Interleukin |
|||
| Adoptive cell transfer | TILs CIK cells CAPRI cells TCR cells CAR cells NK cells LAK |
EBR2 MART-1 CD19 |
Bile duct CA, lymphoma, melanoma | ||
| Active | Checkpoint inhibitors | Ipilimumab Nivolumab Atezolizumab |
CTLA-4 PD-1 PD-L1 |
Melanoma, NSCLC,RCC, lymphoma … | |
| Vaccines | Peptide vaccines | Oncophage | RCC | RCC | |
| DC vaccines | Sipuleucel-T | GM-CSF | PRC | ||
| Allogenic whole-cell vaccines | CD4, CD8 | Melanoma, PaC, BRC … | |||
| Oncolytic viruses | T-vec | Melanoma | |||
ADC, Antibody-drug conjugates;BRC, Breast cancer; CD, Cluster of differentiation; CRC, Colorectal cancer; CTLA, cytotoxic T-lymphocyte-associated Protein; EGFR, Epidermal Growth Factor Receptor; GM-CSF, Granulocyte-macrophage colony-stimulating factor; HER2, human epidermal growth factor receptor 2; MART, melanoma antigen recognized by T cells; NSCLC, Not small cell lung cancer; PD, programmed death; PD-L, programmed death-ligand; PRC, Prostate cancer; PaC, Pancreas cancer; RCC, Renal cell cancer;VEGFA, Vascular endothelial growth factor A.